Dysregulation of KRAS signaling in pancreatic cancer is not associated with KRAS mutations and outcome

Pancreatic ductal adenocarcinoma (PDAC) is a tumor with a poor prognosis, and no targeted therapy is currently available. The aim of the present study was to investigate the prognostic significance of the expression of V-Ki-ras2 Κirsten rat sarcoma viral oncogene homolog (KRAS), downstream signaling...

Descripción completa

Detalles Bibliográficos
Autores principales: Lemstrova, Radmila, Brynychova, Veronika, Hughes, David J., Hlavac, Viktor, Dvorak, Pavel, Doherty, Joanne E., Murray, Helena A., Crockard, Martin, Oliverius, Martin, Hlavsa, Jan, Honsova, Eva, Mazanec, Jan, Kala, Zdenek, Lovecek, Martin, Havlik, Roman, Ehrmann, Jiri, Strouhal, Ondrej, Soucek, Pavel, Melichar, Bohuslav, Mohelnikova-Duchonova, Beatrice
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2017
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5661609/
https://www.ncbi.nlm.nih.gov/pubmed/29113235
http://dx.doi.org/10.3892/ol.2017.6946

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5661609/
https://www.ncbi.nlm.nih.gov/pubmed/29113235
http://dx.doi.org/10.3892/ol.2017.6946

Ejemplares similares